Safety and Efficacy of Rivastigmine in Adolescents with Down Syndrome: A Preliminary 20-Week, Open-Label Study

Individuals with Down syndrome (DS) exhibit a cholinergic deficiency similar to that found in Alzheimer’s disease. Cholinesterase inhibitors, used to treat Alzheimer’s disease, may improve cognitive function in individuals with DS. This is the first investigation of the safety and efficacy of rivast...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Heller, James H., Spiridigliozzi, Gail A., Crissman, Blythe G., Sullivan, Jennifer A., Eells, Rebecca L., Li, Jennifer S., Murali Doraiswamy, P., Ranga Krishnan, K., Kishnani, Priya S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2006
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3129997/
https://ncbi.nlm.nih.gov/pubmed/17201619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2006.16.755
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados